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Abstract
Background:  Selective serotonin reuptake inhibitors (SSRIs) are the most common
antidepressants used in first-world countries and are generally well tolerated. Specifically, less
cardiovascular toxicity has been reported in comparison with tricyclic antidepressants. Here we
report QT interval prolongation after an overdose of the SSRI sertraline.
Case presentation: A previously healthy female patient presented with an attempted suicide with
overdoses sertraline (2250 mg), diazepam (200 mg), and temazepam (400 mg). Routine laboratory
studies were normal and her ECG upon admission showed a normal QT interval. The next day,
her ECG showed prolongation of the QTc interval up to 525 ms. After discontinuation of sertraline
the QT interval normalized. Echocardiography and exercise electrocardiography were normal.
After hospitalization, the patient resumed sertraline in the normally recommended dose and QT
interval remained within normal ranges.
Conclusion: It seems that the SSRI sertraline in overdose may cause QT interval prolongation.
Background
Since their introduction in 1987, the use of Selective Sero-
tonin Reuptake Inhibitors (SSRIs) has increased dramati-
cally [1]. They clearly have a more favorable safety profile
compared to tricyclic antidepressants [2], although pro-
longation of the QT interval has been reported as a side
effect [3]. This is an important side effect since prolonga-
tion of the QT interval is strongly associated with life-
threatening arrhythmias, most notably torsades de
pointes. Although sertraline belongs to the same class of
antidepressants, controversy persists whether this holds
true for the SSRI sertraline [4]. Here we here present a
patient with prolonged QT interval after sertraline
overdose.
Case presentation
A 40-year old female patient was referred to our emer-
gency department because of an intended overdose with
200 mg diazepam, 400 mg temazepam, and 2250 mg
sertraline.
Her main complaints were fatigue and drowsiness. Blood
pressure, pulse rate, and auscultation of the heart and
lungs were normal. The patient was treated with sodium-
sulfate and charcoal and was admitted to the intensive
care unit for continuous control of vital signs. Routine
laboratory studies (hematology, chemistry) were normal.
Plasma levels of diazepam and temazepam were elevated,
1155 ugr/l (normal: 125 – 750 ugr/l) and 1710 ugr/l
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ECGs of the patient Figure 1
ECGs of the patient. ECG of the patient upon admission (upper panel) shows a normal sinus rhythm with a QT interval in lead 
V2 of 370 ms (QTc 420 ms). There were negative T-waves in leads V1–V3. A second ECG was obtained one day after admis-
sion (lower panel) shows a markedly prolonged QT interval of 520 ms in V2 (QTc 525 ms).BMC Emergency Medicine 2005, 5:5 http://www.biomedcentral.com/1471-227X/5/5
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(normal: 300–900 ugr/l, respectively). Plasma levels of
sertraline and desmethylsertraline were 174 ug/l (normal
20–55 ug/l [5]) and 276 ng/l, respectively.
Her ECG upon admission (upper panel of the figure)
shows a sinus rhythm (77 b.p.m.) without conduction
disturbances. QT interval in lead V2 was 370 ms. We used
the Bazett method (QT time divided by the square root of
the RR interval) to calculate the corrected QT (QTc). QTc
at admission was 420 ms and negative T-waves were
found in leads V1–V3. A second ECG, taken one day after
admission (lower panel of the figure), showed a markedly
prolonged QT interval with deepened negative T waves in
leads V1–V3. QT interval was 520 ms in V2, at a heart rate
(HR) of 63 b.p.m (QTc 525 ms). An old ECG (august
2002) showed a sinus rhythm with a HR of 63 b.p.m and
a QT interval in lead V2 of 370 ms (QTc 373 ms; ECG not
shown).
After 4 days the patient was discharged to a psychiatric
hospital because the risk for another suicide attempt was
deemed high by the psychiatric consultant. After dis-
charge, the patient underwent further out-patient cardiac
evaluation. Echocardiography revealed no structural heart
disease. On exercise electrocardiography, patient reached
88% of her maximum HR – no abnormal ST-segment
changes were observed. Hereafter, the use of sertraline was
resumed in a dose of 50 mg twice daily under guidance of
her psychiatrist. Control ECG revealed a normal QT inter-
val (not shown).
Discussion
We here present a patient with prolonged QT interval
associated with sertraline overdose. An acquired cause of
QT prolongation was suspected since QT intervals had
been normal on admission, about 3 hours after ingestion
of 2250 mg of sertraline (11 times the maximum maxi-
mum recommended dose of 200 mg/day), and were
markedly prolonged after one day in hospital. The QT
interval normalized after sertraline withdrawal. Therefore,
a temporal relation existed between the overdose of sertra-
line and the development of QT prolongation. However,
other causes for QT prolongation, both acquired and
inherited, must be considered. For example, combina-
tions of psychoactive drugs have been shown to cause pro-
longation of the QT interval [6], and our patient ingested
temazepam as well as nitrazepam in overdose.
Whereas previous clinical studies [7-10] did not reveal any
QT prolongation as a side-effect of sertraline, this case
report suggests it may have this potential. We are aware of
1 additional report by Amin et al [11] who described 'a
clinically significant' increase in QT interval after treat-
ment with 200 mg of sertraline, however the magnitude of
QT prolongation was not specified.
Naturally, implications of this finding are limited because
it is only a single case. Two other limitations deserve com-
ment. First, we did not perform a rechallenge with high
dosage of sertraline, since this would be unethical. Sec-
ond, only one blood sample was taken to assess plasma
concentration of sertraline – the sertraline plasma level
was found clearly increased according to other reports
[5,12]. It was therefore not possible to investigate the rela-
tion between the course of QT interval prolongation and
their paralleled serum levels of sertraline
Conclusion
Our observation suggests that the SSRI sertraline may
have the potential to prolong QT interval in rare cases.
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